VX-121/TEZ/D-IVA

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

107 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

1

Ibsrela

AArdelyx

Phase 3

12

Zyvox

Pfizer

Phase 2

23

Lamprene

Novartis

Phase 2

14

HSK31858

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

25

ELX/TEZ/IVA

Vertex Pharmaceuticals

Phase 3

186

Trimethoprim-Sulfamethoxazole

Astellas

Phase 2

17

Trikafta

NNottingham University Hospitals NHS Trust

Phase 3

48

VNZ/TEZ/D-IVA

Vertex Pharmaceuticals

Phase 3

19

Verapamil Hydrochloride

Mylan Pharmaceuticals Inc

Phase 3

110

Hyperpolarized Xenon-129

TThunder Bay Regional Health Research Institute

Phase 3

1Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Cystic Fibrosis4 trials

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Completed·Vertex Pharmaceuticals·Phase 3·NCT05076149·597 enrolled

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Recruiting·Vertex Pharmaceuticals·Phase 3·NCT05422222·210 enrolled

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Completed·Vertex Pharmaceuticals·Phase 3·NCT05033080·435 enrolled

Show 1 more trial

A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121/TEZ/D-IVA Combination Therapy in Subjects With Cystic Fibrosis

Active, not recruiting·Vertex Pharmaceuticals·Phase 3·NCT05444257·822 enrolled

Moderate Hepatic Impairment1 trial

Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Completed·Vertex Pharmaceuticals·Phase 1·NCT05437120·16 enrolled

Unspecified1 trial

A Study to Evaluate the Relative Bioavailability of a Fixed-dose Combination Tablet of VX-121/Tezacaftor/Deutivacaftor

Completed·Vertex Pharmaceuticals·Phase 1·NCT05535959·16 enrolled

Details

Drug Info

Related News